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Management Program for Lymphatic Filariasis in Odisha State, India
Abstract
Lymphatic filariasis afflicts 68 million people in 73 countries, including 17 million persons living with chronic
lymphedema. The Global Program to Eliminate Lymphatic Filariasis aims to stop new infections and to
provide care for persons already affected, but morbidity management programs have been initiated in only 24
endemic countries. We examine the economic costs and benefits of alleviating chronic lymphedema and its
effects through a simple limb-care program. For Khurda District, Odisha State, India, we estimated lifetime
medical costs and earnings losses due to chronic lymphedema and acute dermatolymphangioadenitis
(ADLA) with and without a community-based limb-care program. The program would reduce economic
costs of lymphedema and ADLA over 60 years by 55%. Savings of US$1,648 for each affected person in the
workforce are equivalent to 1,258 days of labor. Per-person savings are more than 130 times the per-person
cost of the program. Chronic lymphedema and ADLA impose a substantial physical and economic burden on
the population in filariasis-endemic areas. Low-cost programs for lymphedema management based on limb
washing and topical medication for infection are effective in reducing the number of ADLA episodes and
stopping progression of disabling and disfiguring lymphedema. With reduced disability, people are able to
work longer hours, more days per year, and in more strenuous, higher-paying jobs, resulting in an important
economic benefit to themselves, their families, and their communities. Mitigating the severity of lymphedema
and ADLA also reduces out-of-pocket medical expense.
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represent the views of CDC.
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Abstract. Lymphatic filariasis afflicts 68 million people in 73 countries, including 17 million persons living with chronic
lymphedema. The Global Programme to Eliminate Lymphatic Filariasis aims to stop new infections and to provide care
for persons already affected, but morbidity management programs have been initiated in only 24 endemic countries. We
examine the economic costs and benefits of alleviating chronic lymphedema and its effects through a simple limb-care
program. For Khurda District, Odisha State, India, we estimated lifetime medical costs and earnings losses due to chronic
lymphedema and acute dermatolymphangioadenitis (ADLA) with and without a community-based limb-care program.
The program would reduce economic costs of lymphedema and ADLA over 60 years by 55%. Savings of US$1,648 for
each affected person in the workforce are equivalent to 1,258 days of labor. Per-person savings are more than 130 times
the per-person cost of the program. Chronic lymphedema and ADLA impose a substantial physical and economic burden
on the population in filariasis-endemic areas. Low-cost programs for lymphedema management based on limb washing
and topical medication for infection are effective in reducing the number of ADLA episodes and stopping progression of
disabling and disfiguring lymphedema. With reduced disability, people are able to work longer hours, more days per year,
and in more strenuous, higher-paying jobs, resulting in an important economic benefit to themselves, their families, and
their communities. Mitigating the severity of lymphedema and ADLA also reduces out-of-pocket medical expense.
INTRODUCTION
Lymphatic filariasis (LF) afflicts an estimated 68 million peo-
ple in 73 countries of Africa, Asia, Oceania, and the Americas1
and is one of the diseases targeted for elimination by the
World Health Assembly (World Health Assembly Resolution
WHA 50.29: Elimination of lymphatic filariasis as a public
health problem. Fiftieth World Health Assembly, 5–14 May
1997, Resolutions and Decisions). The Global Programme to
Eliminate Lymphatic Filariasis (GPELF) embodies two “pil-
lars”: stopping new infections by the year 2020 and managing
morbidity and preventing disability for persons already
infected.2 Of the 73 endemic countries, 62 had initiated mass
drug administration (MDA) for elimination of new infections
as of 2014.3,4 As of 2015, 45 countries were considered “on
track” to achieve elimination targets by 2020.5
An estimated 36 million people live with the disabling effects
of LF, including about 17 million persons with chronic lymph-
edema, primarily of the legs, and also of the arms, breasts, and
scrotum, and 19 million men with hydrocele.1 The remaining
LF-infected persons are at risk of developing lymphedema or
hydrocele. Programs to manage morbidity and prevent disabil-
ity among infected persons, the second pillar of the GPELF,
had been initiated in only 24 of the 73 endemic countries by
2014.4 This article examines the economic costs and benefits
of one such program of morbidity management and disability
prevention (MMDP) for alleviating the causes and effects of
chronic lymphedema. Interventions for hydrocele differ from
those for lymphedema and are not included in this study.
Nature of the disease. Larval forms ofWuchereria bancrofti,
Brugia malayi, and Brugia timori are transmitted to humans
by different species of mosquitoes, depending on world region.
Lymphatic vessels are damaged by the presence of adult
worms, causing lymphedema that worsens with age. Lymph-
edema is generally considered an adult condition, but dam-
age to lymph vessels from filarial infection can begin in
childhood.6,7 The progressive worsening of lymphedema is
not inevitable; rather it is accelerated by recurrent episodes
of acute dermatolymphangioadenitis (ADLA), disabling
bouts of fever and intense pain lasting several days that are
caused by bacterial infections.8,9 These infections generally
enter the lower limbs where the skin is damaged by wounds
or interdigital fungal infections.8,10
Each episode of ADLA further damages the lymph system
and contributes to progression of chronic lymphedema, the
severity of which has been classified into seven stages by
Dreyer and others.8,10 In stage 1, lymphedema is generally
relieved by limb elevation overnight. By stage 7, lymphedema
is characterized by deep skin folds, knobs or protrusions,
mossy lesions, interdigital lesions, and bad odor; the lymph-
edema usually extends above the knee and prevents activities
of daily living.8,10 Worsening lymphedema increases vulnera-
bility to entry lesions that lead to ADLA, which in turn
worsens lymphedema. Several studies confirm the higher inci-
dence of ADLA at higher stages of lymphedema,11–18 but
others do not.19–21 Nevertheless, “[t]he epidemiologic associa-
tion between ADLA frequency and stage, as well as extensive
clinical experience from both filariasis-endemic and non-
endemic areas, strongly suggest that ADLA episodes are a
major—likely the most important—factor in lymphedema
progression, particularly in filariasis-endemic areas.”11
Prevention of increasing disability. With recognition of the
causes of ADLA and their role in progressive worsening of
lymphedema came the realization that very simple and low-
cost methods could prevent recurrent ADLA episodes and
thus lymphedema progression. Washing the legs and feet
with soap and clean water, drying the limbs with clean towels,
applying antifungal creams or antibiotic ointments to inter-
digital lesions, elevating affected limbs, exercising to improve
lymphatic and venous drainage, and wearing shoes have been
shown to be effective in reducing the number of episodes
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of ADLA12,15,17,22–34 (see Supplemental Information for
additional discussion). Several studies have also found that
limb hygiene was associated with reduced leg volume and
regression in lymphedema stage.25,31,35
Very simple interventions can have a substantial impact on
quality of life. Each episode of ADLA can mean several days of
excruciating pain. Lymphedema limits mobility and daily activi-
ties; it can be disfiguring and lead to stigma. Reducing ADLA
and lymphedema allows LF-affected persons to engage more
easily in family and community life as well as employment.
Previous studies of the economic cost of LF. Numerous
studies have described the economic cost imposed by ADLA
or lymphedema. When people seek medical attention for their
chronic lymphedema or during an ADLA episode they incur
out-of-pocket expenses for consultations, tests, medications,
and transportation costs. The quantitatively more important
components of the lifetime economic cost of LF are the lost
earnings in paid employment and loss of unpaid household
labor. Those with lymphedema or ADLA may be forced to
work fewer days per year or fewer hours per day and may earn
a lower wage because they cannot engage in strenuous labor.
Chu and others36 estimated the benefits of MDA from the
first 8 years of the GPELF. They included patient out-of-
pocket costs of medical consultations, medications and travel,
lost wages due to reduced hours of work or days lost to
ADLA, and medical costs to the public sector. They found
that the economic cost of LF could be reduced by at least
US$20 billion by preventing transmission of filarial infection.
Two studies in Odisha State (formerly Orissa), India, found
that the average annual out-of-pocket cost for medical care
for lymphedema and ADLAwas about US$14,37,38 more than
10 times the average daily wage of unskilled rural workers in
the state.39 Studies elsewhere in India and in other countries
also found substantial out-of-pocket costs for medical care for
lymphedema and ADLA.40–44
Each ADLA episode leads to a loss of 3–12 days of work,
with an average reported in India of more than 4 days; annual
incidence of ADLA varies widely among different studies in
India, ranging from 1.6 to 7.6 episodes.11,15,40,45–50 Chronic
lymphedema at advanced stages can be completely disabling
and prevent wage employment or the performance of house-
hold tasks. Those at intermediate stages of lymphedema may
have partial disability with substantial earnings loss. For exam-
ple, daily output measured in yards of cloth was found to be
27% lower for weavers with lymphedema than for those
without.51 Estimates of reduced time spent in paid or unpaid
employment (measured in either hours per day or days per
year) for those with lymphedema range from 13.0% to
19.5%.38,42,44,49,51,52 Together with out-of-pocket medical
costs, those earnings losses are an extraordinary economic
burden on some of the poorest people in India.
A COMMUNITY-BASED PROGRAM IN KHURDA
DISTRICT, ODISHA STATE, INDIA
The present work examines the economic costs and benefits
of the lymphedema management program implemented by the
Church’s Auxiliary for Social Action (CASA), an Indian non-
governmental organization (NGO), with technical assistance
provided by the U.S. Centers for Disease Control and Pre-
vention. In 2005, 40 local NGOs conducted a house-to-house
census of 1.3 million persons in the rural and peri-urban areas
of Khurda District in Odisha State, an LF-endemic area, and
identified all residents with lower-limb lymphedema, record-
ing age, gender, lymphedema stage, and number of ADLA
episodes in the previous year.53–55 From 2007 to 2010, CASA
provided services to more than 21,000 persons identified in
1,447 villages in a community-based program utilizing commu-
nity health workers to train LF patients in leg washing and use
of topical antibiotic and antifungal treatments.54 In 2009 to
2011, 370 patients from villages not yet enrolled in the CASA
program in Khurda were recruited in a prospective cohort study
examining the effectiveness of the lymphedema management
program. Participants reported a significant decrease in per-
ceived disability after 2 years in the program, with greater
improvements in patients with moderate or advanced lymph-
edema. Patients also reported losing 2.5 fewer work days per
month after 1 year in the program.56
In another study of the 370 patients in the limb-care
program, ADLA episodes decreased 34% over 24 months.
The percentage of persons whose lymphedema progressed
(worsened) decreased and the percentage of those whose
lymphedema regressed (improved) increased. Use of soap was
associated with decreased incidence of ADLA among per-
sons without entry lesions.35 Per-person program costs were
US$10.00 to US$12.50 for the 24 months. Based on 29 days of
lost productivity per year recovered as a result of the limb-
hygiene program, it was estimated that 1,600 person-years of
labor were saved in the first year of the CASA program
covering more than 21,000 people.54 Clinical data for this eco-
nomic analysis are based on the 2005 census and the pilot
studies of 2009–2011 mentioned above.
METHOD
Although the individual experience of persons with lymph-
edema due to LF varies, there is a general tendency, in the
absence of intervention, toward increasing stage of chronic
lymphedema and increasing frequency and severity of ADLA
episodes with age.57–59 The purpose of MMDP for people
with lymphedema is to prevent ADLA and stop the progres-
sion of chronic lymphedema. We began by calculating the age
distribution of chronic lymphedema and number of ADLA
episodes per year for the population in the 2005 census of
households in Khurda District mentioned above. We grouped
people from 8 to 72 years of age into 5-year age cohorts and
calculated the number of people at each stage of lymphedema
and the number of ADLA episodes in the previous year for
each age cohort. Using Microsoft Excel (Microsoft Corpora-
tion, Redmond, WA), we estimated the economic cost of mor-
bidity and disability over the working lives of affected persons
without lymphedema management and the projected reduc-
tion in those costs that would result from implementation of a
community-based lymphedema management program.
Age distribution of lymphedema stage and ADLA without
and with lymphedema management. We postulated two
scenarios. In both scenarios, MDA has ended transmission
of the LF parasite, but it has not reduced lymphedema or
ADLA. Every 5 years, the oldest age cohort is retired from
the population and younger cohorts move forward. Below
age 8 years, no newly infected persons enter the treatment
population because of the effects of five rounds of MDA in
stopping transmission of filariasis.1
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In the no-treatment scenario, there was no intervention to
improve limb care, prevent ADLA, or slow progression of
lymphedema. As each cohort ages, its average lymphedema
stage and frequency of ADLA increase so that, 5 years from
now, each group will have the morbidity distribution that its
next older cohort has at present.
In the treatment scenario, we assumed that the community
lymphedema management program on average halts the pro-
gression of lymphedema. In every age cohort, we assumed
that progression of lymphedema stage for some is offset by
regression for others, and thus each age cohort maintains the
same distribution of lymphedema that it had at the beginning
of the lymphedema management program. Based on the
results of the limb-care program in Khurda, we assumed that
the number of ADLA episodes for each age cohort will be
one-third less than that in the no-treatment scenario.35
Costs. Using the two sets of morbidity distributions—ADLA
and lymphedema stage with and without lymphedema
management—we calculated the economic cost for each
scenario. The difference between the two (the cost saving)
is the economic benefit of lymphedema management.
Costs were calculated from the societal perspective, but
we included only out-of-pocket costs to patients and their care-
givers for clinic visits, medical tests, travel, and medications,
and lost earnings for patients due to chronic lymphedema and
ADLA. The earnings loss due to lymphedema and ADLA
episodes arises from fewer work days, fewer hours per day,
and/or lower daily wages. Based on costs reported in the liter-
ature, we calculated the total out-of-pocket costs and lost
earnings with and without lymphedema management for each
age cohort during the initial 5-year period, and then for every
5 years until the cohort ages out of the analysis at the age
of 72 years. The economic benefit from the lymphedema
management program is the difference between the two esti-
mates of the total cost. We then compared the direct costs of
implementing the program to the economic benefits of lymph-
edema management.
All costs were estimated in US dollars for 2008, discounting
future costs at 3% per year. To determine what economists call
the present discounted value, future costs and benefits are
assumed to be worth less than current ones and are weighted
less than those in the near term.60 Real wages (adjusted for
inflation) and real expenditure on medical care were projected
to rise 4% per year. Total cost was estimated over the working
lives of all persons up to age 72. Table 1 lists the parameter
values estimated for the calculation of lifetime out-of-pocket
cost and earnings loss. (See Supplemental Information for
explanation of data sources and derivations of parameter
values for out-of-pocket medical costs, average number of days
worked per year, lost work days due to chronic lymphedema
and ADLA, wage rate, and the rate of increase in real wages
and in the real cost of medical care.)
We used conservative estimates for improvement in
ADLA, stage progression, and lost work days and hours.
Predictions for real wage growth and the cost of medical care
over the next 60 years are subject to considerable uncertainty.
Thus, we performed sensitivity analysis using higher estimates
of lost work days and lower and higher estimates of rate of
growth of real wages and costs, the results of which are
reported in the Supplemental Information.
RESULTS
We found progression of lymphedema with age in Khurda
District as found in other studies.57–59 Table 2 shows the dis-
tribution of lymphedema stage by age, grouped in 5-year
cohorts. From the youngest to the oldest, there is a steady
decrease in the proportion of people in stage 1. For higher
stages, we found the opposite trend. The average lymphedema
stage rises monotonically with age (from 1.20 in the youngest
cohort to 2.35 for people in their 70s.). Table 3 shows the
percentage of persons in each lymphedema stage experienc-
ing 0, 1, 2, and 3 ADLA episodes in the previous year. Our
analysis of the Khurda data confirmed, as some studies have
found11,13–18,48,57 but others have not,19–21,58 that those in higher
stages of lymphedema are likely to have more ADLA episodes.
Economic cost with and without lymphedema management.
Days of work lost due to chronic lymphedema and to ADLA
episodes for each age cohort without an intervention are
shown in the second and third columns of Table 4. We
calculated the lost earnings from partial or total disability
as the total number of work days lost times the average
wage for rural households in Odisha State. Derivation of
work days lost and the wage is described in the Supplemen-
tal Information.
Current out-of-pocket spending for medical attention for
lymphedema and for ADLA episodes for each age cohort is
shown in the fifth and sixth columns of Table 4.
We calculated the economic cost of lymphedema and ADLA
in two scenarios, with and without a community-based lymph-
edema management program. Without the program, each
cohort would progress through lymphedema stages as had
older cohorts and more people would experience episodes of
ADLA, replicating the experience of older cohorts. The total
economic cost of lymphedema and ADLA is calculated as
the present discounted value of the sum of out-of-pocket
costs and lost earnings over the working lives of all persons
TABLE 1












Annual increase in real cost
of medical care for chronic
lymphedema and ADLA
4% 61–66
Annual discount rate 3% 60
Average daily wage rate US$1.31 39
Annual increase in real wages 4% 61–66
Lost work days per episode
due to ADLA
4 37
Average number of days worked
per year
289 67
Percentage of work days







ADLA = acute dermatolymphangioadenitis.
*Derivation of values is explained in Supplemental Information.
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with morbidity identified in Khurda. For this population, the
total lifetime economic cost without lymphedema manage-
ment is US$47.4 million.
We then calculated the economic cost for this population in
a scenario with community-based lymphedema management;
people on average remain in the same stage of lymphedema
over time and experience on average one-third fewer ADLA
episodes per year than they would have without the limb-care
program. This scenario, based on the results of the Khurda
limb-care program, represents a substantial gain in quality of
life for more than 17,000 people who can expect a reduction
in number of episodes of ADLA and stabilization of lymph-
edema stage or possible improvement. The present value of
the total economic cost for this population after lymphedema
management is US$21.3 million.
The present value of the benefit of lymphedema manage-
ment (the reduction in economic cost) for this population
is US$26.1 million, or US$1,648 per participant of working
age. When the community-based lymphedema management
program was implemented in Odisha, the average daily
wage for low-skilled agricultural workers in the state was
US$1.31.39 Thus, the present value of per-person economic
benefit from the limb-care program was equivalent to
1,258 days of earnings. To implement and operate the Khurda
community-based lymphedema management program for
2 years cost between US$10.00 and US$12.50 per person.35
The average participant in the program can expect lifetime
economic benefits that are between 132 and 165 times the
per-person cost of the program. The results are robust to
changes in parameters for wage and price increases and work
days lost (see Supplemental Information for sensitivity tests of
our assumptions about parameter values).
DISCUSSION
Lymphedema and episodes of ADLA in filariasis-endemic
areas diminish the quality of life of affected persons due to
pain, stigma, numerous days of illness each year, restricted
mobility, and reduced participation in family and community
life. They also impose a substantial economic cost on affected
persons and their families and diminish the potential eco-
nomic strength of communities. Programs to provide care for
persons with lymphedema and ADLA (as well as hydrocele)
in filariasis-endemic areas are mandated by the GPELF.
Beyond the ethical mandate to improve quality of life for
affected persons, there are strong economic arguments for
investing in the care of persons affected by filariasis, which
the results of this research confirm. With adequate limb care,
patients are better able to support themselves and provide
for their families. Children and other dependents of affected
persons could have greater access to better nutrition and the
TABLE 3
ADLA episodes in previous year experienced by persons in each
lymphedema stage in Khurda census, 2005
Stage of lymphedema
Percentage of persons in each stage with ADLA episodes
0 episode 1 episode 2 episodes 3 episodes Total
1 17.1 68.7 7.8 6.4 100.0
2 16.1 71.4 7.2 5.2 100.0
3 15.2 69.4 9.2 6.3 100.0
4 14.2 68.5 9.6 7.7 100.0
5 15.7 58.7 12.3 13.3 100.0
6 10.8 62.1 12.8 14.3 100.0
7 12.6 57.1 15.1 15.1 100.0
Average 16.1 69.3 8.2 6.4 100.0
ADLA = acute dermatolymphangioadenitis.
TABLE 2
Stage of lymphedema by age cohort in Khurda census, 2005
Age cohort (years) Number of respondents
Percentage of age cohort at each stage of lymphedema
Average stage
Stage of lymphedema
1 2 3 4 5 6 7 Total
8–12 74 86.5 6.8 6.8 0.0 0.0 0.0 0.0 100.0 1.203
13–17 137 78.8 15.3 2.9 2.2 0.0 0.7 0.0 100.0 1.314
18–22 267 70.4 18.0 8.6 2.6 0.0 0.0 0.4 100.0 1.453
23–27 443 61.9 24.6 9.5 2.9 0.2 0.9 0.0 100.0 1.578
28–32 866 56.8 24.0 15.1 2.2 0.7 0.9 0.2 100.0 1.696
33–37 1,158 47.8 30.3 16.4 3.7 0.7 0.5 0.6 100.0 1.832
38–42 1,845 43.0 29.7 19.1 5.0 1.2 1.0 1.0 100.0 1.987
43–47 1,789 40.9 29.2 21.0 5.5 1.7 1.2 0.6 100.0 2.037
48–52 2,257 38.0 29.2 23.4 6.0 1.7 1.0 0.8 100.0 2.104
53–57 1,723 34.5 28.1 25.2 8.9 1.7 0.8 0.8 100.0 2.208
58–62 2,441 31.0 30.1 25.8 8.6 2.5 1.4 0.6 100.0 2.280
63–67 1,400 29.3 31.2 25.8 9.1 2.0 1.9 0.7 100.0 2.318
68–72 1,453 29.9 28.4 26.8 10.1 2.3 1.7 0.8 100.0 2.352
Total 15,853 39.5 28.6 21.9 6.6 1.6 1.1 0.7 100.0 2.084
TABLE 4
Work days lost annually, annual earnings lost, and annual out-of-pocket
medical costs due to lymphedema and ADLA for each age cohort


















18–22 2,630 1,084 US$4,865 US$2,926 US$553
23–27 5,751 1,796 US$9,887 US$4,855 US$916
28–32 14,941 3,568 US$24,247 US$9,491 US$1,820
33–37 23,265 4,784 US$36,744 US$12,692 US$2,440
38–42 50,835 7,568 US$76,508 US$20,221 US$3,860
43–47 53,754 7,460 US$80,190 US$19,607 US$3,805
48–52 72,626 9,204 US$107,197 US$24,737 US$4,694
53–57 63,725 7,096 US$92,775 US$18,884 US$3,619
58–62 98,405 10,224 US$142,303 US$26,753 US$5,214
63–67 57,858 6,196 US$83,910 US$15,344 US$3,160
68–72 64,245 6,192 US$92,272 US$15,925 US$3,158
ADLA = acute dermatolymphangioadenitis.
*See Supplemental Information for derivation of values.
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opportunity to attend school if the wage earner is healthier.
Family members are relieved of the burden of caring for per-
sons who are bedridden due to ADLA or advanced lymph-
edema and can contribute better to household income and
domestic tasks. The community’s economy is strengthened
with fewer of its members disabled by lymphedema and
ADLA and fewer of its families in poverty.
Extent of the problem. Our dataset was based on a mor-
bidity census that was taken by visiting every household in
the rural and peri-urban areas of Khurda District and found
more than 17,000 persons with some degree of lower-limb
lymphedema, 1.3% of the regional population.55 Two-thirds
of persons with lymphedema, however, were in stage 1 or 2.
These results suggest the possible invisibility of persons in
other locations who have subclinical lymphatic damage due to
LF infection, early-stage lymphedema, or infrequent episodes
of ADLA and who remain at risk for worsening ADLA,
advanced lymphedema, and disability. Where morbidity esti-
mates are based not on a census, but on the number of people
who seek treatment of chronic lymphedema, ADLA, or
hydrocele, prevalence could be greatly underestimated.
Another issue highlighted by the Khurda census data is
the long time horizon of lymphedema and ADLA and their
ongoing economic cost. Even if new infections are stopped
by 2020, some people whose lymph vessels are already dam-
aged will experience ADLA episodes and lymphedema for the
rest of their lives. Lymphedema and ADLA can necessitate
out-of-pocket medical costs and cause a loss of earnings from
reduced hours, absenteeism, and reduced intensity of work
for 60 years or more. Indeed, the younger the cohort, the
greater are the economic losses that accrue over their working
lives. Thus, it is of critical importance to begin lymphedema
management as soon as possible and to include young people
and others who may have subclinical lymphatic damage and
few or no ADLA episodes. Very low-cost interventions initi-
ated now can save a lifetime of suffering and lost earnings.
Potential benefits nationally and internationally. Implemen-
tation of lymphedema management throughout India would
reap benefits many times greater than in Odisha alone, one
of the poorest Indian states. In ranking 20 Indian states by
the daily wage rate, Odisha is in the bottom quartile in nine of
10 unskilled rural occupations (Table 3a in Labour Bureau39).
Even though LF generally affects the poorest people, in most
other states, rural wages at all levels are higher than in Odisha.
Consequently, the earnings loss of lymphedema and ADLA
would be greater and the benefits of a lymphedema manage-
ment program would also be greater in other Indian states
than in Odisha. In other countries, community- and clinic-
based limb-care programs have demonstrated the efficacy of
low-cost interventions in reducing the number of ADLA epi-
sodes and stabilizing or improving lymphedema stage. It is rea-
sonable to conclude that those improvements in quality of life
would also yield economic benefits. Since the largest compo-
nent of the cost of lymphedema and ADLA is the loss of
wages—and the largest benefit is regained productivity—it is
likely that gains elsewhere would be greater than in Odisha
because it has lower wages than in most other LF-affected areas.
A public health approach: integration with other programs.
Every filariasis-endemic country has numerous other serious
health problems competing for scarce resources, whether from
government sources or community NGOs. While some aspects
of elimination programs may require a vertical, or disease-
specific, approach, policymakers are finding that integration
of control programs for multiple diseases can have logistical
and economic advantages.
With morbidity management as well, there could be impor-
tant advantages to integrated programs. Limb care in particular
might be integrated across several diseases common in India
and in other countries. India has the world’s highest burden
of Hansen’s disease (leprosy),68 also present in several other
LF-endemic countries, which can necessitate lifelong limb
care. There are an estimated 4 million people globally with
podoconiosis, for whom limb treatment is similar to that for
LF.69 Diabetes, now common in affluent countries, is an
increasing problem in low- and middle-income populations.
Foot protection, wound care, and limb hygiene are all impor-
tant for diabetes care as well. Providing education and support
for people with limb-care needs can be carried out in the
public sector or in NGO-run programs, whether at the health
facility or community level, with the potential for substantial
cost economies as well as social benefits. Integrated programs
can help reduce the social isolation of disfiguring and debili-
tating diseases. The emphasis on rehabilitating people in tradi-
tionally marginalized groups, such as people with Hansen’s
disease and LF, and helping them maintain their work perfor-
mance or return to participation in community life, carries an
important message of inclusion.70
Programs to educate people in limb washing require access
to clean water. Water, sanitation, and hygiene (WASH) pro-
grams are essential for limb care, as well as to reduce breeding
grounds for species of mosquito vectors of LF that flourish in
open sewers. Reduced costs for limb-care programs, as well as
reduced disability for LF patients, are important externalities
that should be included in estimations of the benefits of
WASH programs.
Limitations. To model the economic impact over the life-
times of those with lymphedema and ADLA, we have made
conservative assumptions about labor markets, the impact of
disability on productivity, length of working life, and other
parameters. We assumed flexible labor markets that could
absorb workers who are rehabilitated through lymphedema
management programs without exerting downward pressure
on wages. This is reasonable because, although LF morbidity
is a serious problem in endemic areas, the number of people
affected is still a small proportion of the available labor force.
Increases in labor supply from reduced morbidity would have
little effect on the labor market because the expected gains
from lymphedema management programs extend over the
working lives of cohorts, rather than acting as a shock to labor
markets at a moment in time. Moreover, any increase in earn-
ings in the wake of a lymphedema management program is
likely to be spent in the local economy, which could stimulate
job growth and offset any downward pressure on wages from
increased labor supply. We have not included a local multi-
plier effect and therefore the economic benefit of the inter-
vention over time is substantially underestimated.
While the present analysis shows substantial gains from a
community-based lymphedema management program for the
Khurda population—US$26.1 million or US$1,648 per person
enrolled—we think that those figures underestimate the eco-
nomic costs of untreated LF morbidity and the benefits of
lymphedema management. Our baseline estimate for earnings
loss due to chronic lymphedema and ADLA was below the
range found in several other studies. We did not include lost
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work time for youths until they reach the 20-year cohort,
although young people in poor rural areas are generally
employed, even below the age (15 years) included in govern-
ment employment statistics. In addition, we chose only low-
wage occupations in rural areas (omitting semi-skilled trades
with higher wages) to set the daily wage rate in our modeling.
Finally, we assumed that a successful lymphedema manage-
ment program would freeze the age structure of lymphedema.
Recent studies, however, find that lymphedema management
leads to net regression of lymphedema stage as well as reduc-
tion in the number of ADLA episodes.12,15,17,23–35,56
This study underestimates the costs of LF morbidity and
the benefits of lymphedema management in other ways. We
have attempted to measure only the economic costs that fall
directly on persons with chronic lymphedema and ADLA in
a filariasis-endemic area. We exclude costs to others, includ-
ing society as a whole or government. Subsidized care in
government-run clinics, for example, is ultimately financed
by the taxpayer. Reducing disease progression and disability
reduces the need for subsidized care in the future, a benefit
to taxpayers that is not included in our analysis.
We do not include any accounting of other externalities of
chronic lymphedema and ADLA. For example, we do not
include the lost work time of family caregivers for those dis-
abled from ADLA and lymphedema, nor the impact on child
nutrition and schooling, which would affect the child’s future
earnings. Since we have not measured these second-order
costs of morbidity and benefits of lymphedema management
programs, our calculations substantially understate the
reduction in the economic cost of lymphedema and ADLA
that a lymphedema management program would generate.
Chronic lymphedema and episodes of ADLA impose a sub-
stantial physical burden on the population of Khurda District,
a filariasis-endemic area, and that disease burden increases
with age. The economic burden of lymphedema and ADLA
is also substantial. A low-cost program of lymphedema man-
agement based on limb washing and topical medication for
infection can reduce the economic burden on poor populations
affected by filariasis morbidity by 55%. The net benefit per
person over the lifetime is more than 130 times the per-person
cost of the program and equivalent to more than 1,250 days of
earnings for the average person affected by filariasis.
Programs for MMDP are mandated by the twin pillars of
the GPELF. Low-cost interventions have been shown to be
effective in reducing the frequency of episodes of ADLA
and slowing progression of lymphedema. This study demon-
strates that the economic benefits of such interventions far
exceed the costs and result in very significant benefits to
filariasis-affected people and their communities.
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SUPPLEMENTAL INFORMATION
DETAILED METHODS AND SOURCES
This supplement provides detailed information on the
sources used to determine parameter values and the method
of calculating the results for our modeling of the economic
cost of lymphedema and acute dermatolymphangioadenitis
(ADLA) in an area with endemic lymphatic filariasis (LF).
Efficacy of lymphedema management. Numerous studies
have provided evidence of the efficacy of simple programs of
limb care in stopping or reversing progression of lymphedema
and reducing the number of episodes of ADLA. Many
successful lymphedema management programs have been
community-based educational campaigns. The World Health
Organization explained the rationale for community-based
efforts, saying “the social model views disability as a matter
of an individual’s full integration into society and prescribes
social action to make the environmental modifications neces-
sary for the full participation of people with disabilities in all
areas of social life.”1
In Egypt, 2 years after instruction in limb washing and
application of antifungals and antibacterial ointments to
small wounds, participants reported a 57% reduction in
ADLA episodes per year.2 In Nigeria, under community-
based care, 90% fewer patients experienced two episodes of
ADLA per month after 12 months of treatment.3 In Burkina
Faso, after 4½ months of a leg-hygiene program, the percent-
age of patients experiencing an ADLA episode in the pre-
vious month was reduced by half.4 A community program of
home-based care in Sri Lanka found that the number of
persons experiencing one or more ADLA episodes decreased
by 64% (Table 3)5 and 66% perceived reduced lymphedema
after 1 year.5
Most community-based lymphedema management programs
for filariasis reported in the literature have been in India. In
Kerala, 1-day health camps to teach leg washing and care of
bacterial entry points were followed up after 6 months by
questionnaires on disease symptoms (redness, swelling, odor,
wound, and fever) and quality of life. Almost all participants
(96%) reported reduced symptoms after following the
hygiene regimen.6 Also in Kerala, placebo-controlled trials
examined the efficacy of different treatments for reducing
ADLA that included diethylcarbamazine (DEC) and either
ivermectin or penicillin. Participants in all arms were enrolled
in a comprehensive foot-care program.7,8 Improved foot care
was found to be an effective treatment even for those who
received no medication. A follow-up study in which visits
were carried out a year or more later, with no additional
interventions, found a 72.5% reduction in the frequency of
ADLA, confirming the lasting efficacy of education efforts
to reduce morbidity.9
In Tamil Nadu, in a trial of three drugs to prevent ADLA,
all arms of the trial practiced limb hygiene. Even the control
group, practicing only leg washing, had reduced incidence
of ADLA in the treatment year and beyond.10 In two
LF-endemic districts in Kerala and Karnataka States, patients
with grade II and III lymphedema (of grades I–IV) were
trained in limb hygiene in LF camps and evaluated 3 months
later. In Kerala, 25% fewer patients had episodes of ADLA,
and in Karnataka, 73% fewer patients had ADLA episodes11
(see also Ref. 12).
In addition to community-based educational programs, a
few lymphedema management programs have been based in
clinics. In Haiti, one such program emphasizing self-care,
especially washing of the legs, was associated with a 69%
reduction in ADLA episodes for all participants and reduction
in leg volume for participants with stage 2 lymphedema.13 In
another study in Haiti, it was found that washing affected
legs with soap was associated with a reduction of ADLA epi-
sodes from 1.1 to 0.4 per person-year, a 64% reduction, over
the 12-month study.14 In contrast, a clinic-based program in
Togo led to a small, but statistically insignificant, decline in
the number of ADLA episodes and a statistically significant
increase in the number of patients whose lymphedema
prevented them from washing or getting out of bed.15
A recent systematic review and meta-analysis concluded
that the “available evidence strongly supports the effectiveness
of hygiene-based lymphedema management in LF-endemic
areas” for the prevention of ADLA.16 Their meta-analysis
found that participation in such programs was associated
with decreased percentage of patients reporting at least one
episode of ADLA (odds ratio [OR] = 0.29, 95% confidence
interval [CI] = 0.12–0.47) and lower incidence of ADLA
(OR = 0.32, 95% CI = 0.25–0.40).16
Some studies suggest that mass drug administration (MDA)
can reduce lymphedema and frequency of ADLA in persons
already infected,17–26 but other studies do not.10,27–29 Conse-
quently, available evidence does not warrant incorporating in
the model any effect of MDA on lymphedema and ADLA.
The results of the Khurda community-based limb-care pro-
gram are in line with the results discussed above. We based
our parameters—halting progression of lymphedema and
one-third reduction in ADLA episodes—on the literature
above and the outcomes of the Khurda interventions.30,31
Clinical data. The objective of the study is to assess the
economic effect of a morbidity management and disability
prevention program that changes the age distribution of
lymphedema and ADLA in a population over time. We derive
the age distribution of morbidity from a census of house-
holds conducted in 2005 in Khurda District, Odisha State,
India, by 40 Indian nongovernmental organizations. The cen-
sus recorded age, gender, lymphedema stage, and number of
ADLA episodes in the previous year. The data we used were
stripped of personal identifiers and were thus anonymous.
Consequently, no ethical clearance was warranted. We used
Microsoft Excel (Microsoft Corporation, Redmond, WA).
The census generated a list of 21,496 persons. We elimi-
nated cases with no data and those with no lower-limb lymph-
edema, and 17,036 respondents remained in the dataset.
Gender and age distribution of morbidity. From the
Khurda morbidity census data we generated the gender and
age distribution of persons with lymphedema. As shown in
Supplemental Table 1, there is only a small gender difference
in the number of ADLA episodes, as others have found32,33
(for contrary findings, see Refs. 34, 35).
As shown in Supplemental Table 2, there were only small
differences in lymphedema stage between females and males.
The “average stage” was slightly higher for females than males
(2.14 versus 2.06). (Average stage is in quotation marks in the
previous sentence since stage is an ordinal, not a cardinal, vari-
able.) Men were more likely to be in stage 1 lymphedema than
women, and women were more likely to be in stages 2 and 3
than men. There was more gender balance at higher stages.
Start date. CASA scale-up of the lymphedema manage-
ment program was carried out between mid-2007 and mid-
2010, with the largest number of people enrolled in 2008–
2009.36 We took mid-2008 to mid-2009 as our start date and
calculated real wages and out-of-pocket medical costs from
that time.
Age cohorts. Age was reported as ending in 0 or 5 for
72% of respondents, rather than the approximately 20% that
one would expect. Accordingly, we grouped people in 5-year
cohorts: 18- to 22-year-olds belong to the 20-year cohort,
23- to 27-year-olds belong to the 25-year cohort, and so on.
Age limits. The Khurda dataset included persons aged 3 to
99 years. We omitted the 18 children from 3 to 7 years of
age because of small numbers, uncertainty of the cause of
their reported lymphedema and ADLA, and the expected
effect of cleared infection from their having experienced
multiple rounds of MDA at a very young age.18 Ultrasono-
graphic and histological evidence shows lymphatic vessel
damage in infected children long before the typical age at
which lymphedema may become evident, generally around
the age of 20 years.37,38 In India and other endemic coun-
tries, there are reported cases of children in filaria-endemic
zones with lymphedema thought to be of filarial origin.39
Among respondents in the dataset, 1.3% were under the age
of 18 years.
We assumed that those in the 10- and 15-year cohorts
would incur out-of-pocket costs for lymphedema and ADLA
from the beginning of the period calculated. The Indian
Bureau of Labour does not include children under 15 years
in the labor force, and we do not include these two cohorts
in the lost earnings calculations until they reach the 20-year
cohort (minimum age of 18 years). There is no maximum
age listed for labor force participation in the Indian govern-
ment labor statistics, but we calculated only up to the 70-year
cohort (with 72 years as the maximum age) because of the
sharp decline in respondents older than 72 years, Indian life
expectancy of 66 years (http://data.worldbank.org/indicator/
SP.DYN.LE00.IN), and decreased labor force participation.
We calculated economic cost for the 15,853 people aged 8–
72 years.
Women’s labor force participation. We assigned economic
loss to the disability of patients whether or not they were in
the paid labor force. Specifically, women whose only or pri-
mary occupation is to prepare food, care for children or the
sick and elderly, and other domestic activities are necessary
for the household and the community to function as economic
entities. We assign the same number of work days lost to men
and women and the same average wage to each work day lost
by either gender.
Out-of-pocket costs of medical treatment of ADLA per
episode. We calibrated our model based on a study in
Khurda District in 2000–2001 by Babu and Nayak (Table 1)40
who reported that ADLA patients who sought medical care
paid (Indian rupees) 92.3 on average (arithmetic mean) per
episode of ADLA, which was equal to US$2.04. (For this
amount and all other costs reported in rupees, we convert to
U.S. dollars for the appropriate dates using the OANDA
online currency converter at http://www.oanda.com/currency/
historical-rates/).
Babu and Nayak’s estimated cost of US$2.04 per episode
in Khurda is somewhat higher than reported in earlier stud-
ies in other regions of India. Nanda and Krishnamoorthy
(p. 57)41 reported per-episode treatment costs averaging
US$0.46. From the data given in Table 2 in the work of
Ramaiah and others,42 one can calculate the arithmetic mean
of per-episode spending on ADLA, which is US$0.61. Other
studies provide estimates of annual spending on ADLA, not
per-episode costs. Krishnamoorthy43 reported spending of
US$0.69 to US$3.00. In Tamil Nadu, Ramaiah and others
(Table 2)44 estimated the number of ADLA episodes and
total spending by patients on ADLA in India. From those
estimates, one can calculate the annual per-person (but not
per-episode) cost of ADLA: US$1.01 for men and US$0.77
for women. We do not consider reported costs of treating
ADLA in other countries.45–47
Annual out-of-pocket costs of medical treatment of
lymphedema patients. We calibrated our model based on a
study in Khurda District by Babu and others (p. 34)48 who
found that the average male lymphedema patient spent 576
annually and the average female spent 425, the weighted
SUPPLEMENTAL TABLE 1
Number of ADLA episodes in previous year by gender in Khurda census, 2005
Gender Number of respondents
Percentage of females and males having ADLA episodes in 1 year
Average number
of ADLA episodes0 episode 1 episode 2 episodes 3 episodes Total
Female 8,746 16.8 68.8 8.1 6.2 100.0 1.04
Male 8,290 15.3 69.8 8.4 6.6 100.0 1.06
Total 17,036 16.1 69.3 8.2 6.4 100.0 1.05
ADLA = acute dermatolymphangioadenitis.
SUPPLEMENTAL TABLE 2
Stage of lymphedema by gender in Khurda census, 2005
Gender Number of respondents
Percentage of females and males at each stage of lymphedema
Average stage
Stage of lymphedema
1 2 3 4 5 6 7 Total
Female 8,746 34.6 31.3 24.8 6.3 1.7 0.9 0.5 100.0 2.14
Male 8,290 43.4 25.7 19.6 7.2 1.8 1.5 0.9 100.0 2.06
Total 17,036 38.9 28.6 22.3 6.7 1.7 1.2 0.7 100.0 2.10
average of which was 478, or US$10.96. The reported aver-
ages are geometric means, which are lower than arithmetic
means. Even though the geometric mean for some purposes
may offer a better sense of the central tendency of a highly
skewed distribution, the appropriate mean for our modeling is
the arithmetic mean since we estimated spending on medical
services by all lymphedema patients. The estimate based on geo-
metric mean thus understates the cost of treatment and generates
a more conservative estimate of the benefits of the intervention.
Estimates of treatment costs for chronic lymphedema in
other locales and at other times are lower. Nanda and
Krishnamoorthy (p. 57)41 reported per-visit treatment costs
in south India averaging US$0.56 but did not report annual
number of visits. Ramaiah and others (p. 21)49 found that the
geometric mean of annual spending on medical care for
lymphedema patients in south India in 1993–1994 was 76 or
US$2.42. Ramaiah and others (Table 2)44 found annual treat-
ment costs of chronic lymphedema (and hydrocele) to be
US 2.25 and US$1.88 for men and women, respectively, in
India as a whole.
Annual real increase in out-of-pocket treatment costs. We
assumed that the demand for medical services will grow as
household income rises (demand is income elastic). More-
over, since labor is a chief input into medical care provision,
the cost of medical services will also rise as real wages rise.
We assumed that the rate of growth in real (adjusted for
inflation) expenditure on medical services will be the same
as the rate of growth in real wages.
Average daily wage. The wage is useful for estimating the
impact on individuals and their families, as well as the impact
of their reduced spending in the community. It would also be
desirable to measure the lost productivity for society that
morbidity and disability entail. For that purpose, the wage is
an imperfect proxy since it may not accurately measure the
contribution of workers to output, nor the loss of their con-
tribution to society. We estimated the average daily wage of
unskilled, mostly agricultural workers, who comprise almost
all (98%)36 of the people in our dataset and are also represen-
tative of the population across India affected by lymphedema
and ADLA. We calculated the average daily wage in rural
occupations in Odisha State during the crop year July 2008
through June 2009. To determine the average daily wage,
we used data from Wage Rates in Rural India 2008–2009
(Tables 3a–14b),50 which gives average wages for men and
women for every month reported separately for ploughing,
sowing, weeding, transplanting, harvesting, winnowing, threshing,
picking, herding, and unskilled nonagricultural labor. We took
the unweighted (the number of workers in each occupation is
not given) average of wages in those 10 occupations averaged
over 12 months of the crop year. Finally, we averaged men’s
and women’s wages, weighted by their relative presence in the
Khurda census, which was 48.7% male.
Annual increase in real daily wage. Between 2006–2007
and 2011–2012, real GDP in India grew 7.9% annually and
real rural wages grew 6.8% (p. 12)51 (see also Refs. 52–54).
Since 2003, real GDP growth exceeded 9% in 4 years and
7% in 8 years. The OECD projects 6.1% growth of real
GDP in India in 2016, gradually trending downward to about
4.6% annually by 2040.55 Between 2007 and 2011, Odisha
had the most rapid growth in rural wages in India (p. 189).54
Indian economists report the following forces pushing up rural
wages: rapid growth in GDP, a shrinking share of agriculture
in GDP, growth of nonagricultural economic activity in rural
areas, and rapid urbanization due to rapid growth in urban
employment, causing a growing gap between urban and rural
wages and fostering rural labor shortages, growing mechaniza-
tion, and growing demand for skilled agricultural workers.
Other factors include increasing integration of labor markets
across states and national and state government policies that
promote growth in rural wage rates, especially the Mahatma
Gandhi National Rural Employment Guarantee Act, which
has boosted rural wages since 2006 by guaranteeing employ-
ment of at least 100 days/year for low-income workers.51–54
All of that suggests that rural wage growth could easily reach
4% annually over the coming decades. Accordingly, we set
our baseline prediction of real rural wage growth at 4%. The
recent rapid growth in real rural wages may be a harbinger of
even more rapid growth in wages over the coming decades.
Our sensitivity analysis, therefore, explores the possibility that
real rural wages in India could grow as rapidly as 5% annually
over the coming decades.
On the other hand, real farm wages in India grew at an
average annual rate of only 2.9% from 1990 to 2012.51 Fur-
thermore, between 2000 and 2006, real farm wages fell by
nearly 2% annually.51 Despite rapid wage growth in 2006–
2011, both Indian GDP growth and real rural wage growth
slowed sharply in 2012.56 Persistently weak economic perfor-
mance in Europe and the United States is currently a drag on
the Indian economy that could continue long into the future.
All of this could suggest that the baseline assumption of 4%
annual growth in real wages is too optimistic, so the sensitivity
analysis shows the effect on the economic cost of lymphedema
and ADLA if real rural wages continue the 2.9% pace set
between 1990 and 2012.
Days of work lost per year by people with chronic
lymphedema. Lymphedema can reduce one’s ability to engage
in productive work, and we measured that as days of work
lost. Several studies record reduced hours of labor per day,
reduced physical output, absenteeism, and coping by per-
forming less strenuous and lower paid jobs.44,48,49,57–59 We
estimated a composite figure to represent all of the ways that
morbidity reduces productivity and earnings. Lower produc-
tivity that reduces the wage rate is treated as a partial reduc-
tion in days worked and is subsumed into our measure of
days of work lost. To determine the days lost, first we found
the number of days a usually occupied rural laborer in
Odisha could expect to work in a year. We relied on data for
Odisha State from Table 4.1.1.1.1, Average Annual Number
of Days Not Worked by Usually Occupied Men Belonging to
All Classes of Rural Labour Households, from the Rural
Labour Enquiry (61st Round of N.S.S.) 2004–05, Report on
Employment & Unemployment of Rural Labour Households
(Main Report), published by the Labour Bureau of the Gov-
ernment of India.60 The report indicates that men in rural
areas of Odisha State did not work an average of 76 days
during the crop year 2005–2006 because no work was avail-
able or they were not available for work (since they were,
for example, students, pensioners, or disabled). Conse-
quently, usually occupied men in rural Odisha worked an
average of 289 days per year. Many women are engaged fully
or partially in unpaid work. As indicated above, we assigned
women the same number of potential work days as men since
their work in the household is essential to the household and
community economy.
Although there are numerous estimates of lost work time
due to chronic lymphedema, none reports the degree of dis-
ability by stage of lymphedema, measured either as hours or
days of work (and thus lost wages) or reduced wage rates.
For the baseline calculations, we assumed that lymphedema
patients in stages 1 and 2 do not lose any work time due to
symptoms of lymphedema. We assume that lymphedema
patients in stages 5–7 cannot work, losing 289 days of pro-
ductive activity annually because of chronic lymphedema.
We further assumed that patients with stage 3 lymphedema
experience a 20% reduction in work time and patients with
stage 4 lymphedema experience a 50% reduction in work
time as a composite estimate of reduced hours, reduced inten-
sity of work, lower pay grade, and absenteeism. The Khurda
census allows us to compute the number of respondents in
each age cohort at each stage of lymphedema. We multiplied
that number by the average daily wage and summed over all
cohorts and all stages to determine the economic cost of
chronic lymphedema from lost earnings.
Our assumptions about degree of disability at each stage of
lymphedema were quite conservative. They produce an aver-
age of 32 lost work days annually for persons with chronic
lymphedema in stages 1–7. That is much lower than the loss
reported in the work of Ramaiah and others, who found that
in India as a whole those with lymphedema or hydrocele lost
51 days of work annually (Table 3).44 Several studies show that
lost work days for men with lymphedema or hydrocele are
about the same, so Ramaiah and others’ estimate is an appro-
priate indicator of lost work time for lymphedema.48,49,57,58
Our assumptions about lost work time at different stages
of lymphedema result in an 11.2% reduction in work time,
which is substantially lower than other studies have found.
Ramaiah and others (Table 4)49 indicate that lymphedema
patients worked 15.2% less than controls. Ramaiah and
others (Tables 3 and 4)58 reported that those with chronic
lymphedema worked 13.7% less than controls in paid work
and 13.0% less in unpaid domestic work. Babu and others
(Table 3)48 found males with lymphedema worked 15.4%
less than controls and women worked 23.5% less. Babu and
others (p. 714)57 measured a 20.2% drop in earnings for
weavers with lymphedema (8.0% from lower wages and
12.2% from fewer hours worked). Similarly, Ramu and
others (p. 670)59 found that male weavers with lymphedema
produced 27.4% less cloth than those with no lymphedema.
Our baseline assumption about productivity loss from lymph-
edema is thus lower than any other published estimate.
Accordingly, the sensitivity analysis determines the effect of
assuming greater disability among those with lymphedema
than in the baseline analysis, with work time loss as follows:
stage 1 = 0%, stage 2 = 10%, stage 3 = 25%, stage 4 = 50%,
stages 5–7 = 100%. These assumptions produce a 15.2%
average work time loss for all persons in the Khurda census
dataset (or 44 lost work days annually), which is just below
the mean of what other studies have found.
Average length of ADLA episodes/days of work lost from
ADLA. We calibrated our model based on the work of Babu
and Nayak (p. 1104)40 and Babu and others (Table 1)61 who
reported on a study in Khurda District that finds a mean
duration of ADLA episodes of approximately 4 days (3.93 days).
The length of ADLA episodes in adults has been reported in
numerous other studies.34,35,42,44,58,62–68 The range of reported
average duration of an ADLA episode is 3–8.6 days with a
mean duration of 4.86 days.
Discount rate. We used an annual discount rate of 3%, which
is the standard rate used for analyzing health interventions.69
Results of sensitivity analysis. We addressed uncertainty
about appropriate values for some of the parameters in our
modeling with sensitivity analysis. We projected a 4% annual
growth in real wages and a commensurate growth in out-of-
pocket spending for medical services associated with chronic
lymphedema and ADLA. As shown in Supplemental Table 3,
reducing predicted growth in the real wage to 2.9% (the aver-
age rate between 1990 and 2012) reduced the per-person
reduction in the economic cost of lymphedema and ADLA by
23%, from US$1,648 to US$1,263. In the last decade, rural
real wages in India and in Odisha have grown far faster than
2.9%, suggesting that a 5% annual growth in real wages is
within the realm of possibility. Modeling a 5% real wage
growth raised the per-person payoff of implementing a lymph-
edema management program by 29%, to US$2,119.
Our assumptions about the degree of disability caused by
lymphedema at different stages produced a loss in work time
of just over 11%. Other studies on the burdens of lymph-
edema have found a loss of work time between 13.0% and
23.5% with a mean of 15.6%48,49,58 (see also Refs. 57,59). Our
11.2% worktime loss may be appropriate, given that our data
were based on a census that sought to find every person in
the target districts with lower-limb lymphedema. Studies that
recruit participants who come to clinics as patients, for
example, may overrepresent individuals at higher stages of
lymphedema since those with early or mild lymphedema may
not seek health services. In case our estimates were too
SUPPLEMENTAL TABLE 3
Sensitivity testing: variations in wages, prices, and work time loss
Assumptions subject to sensitivity testing
Annual increase in real wages and real
out-of-pocket spending on medical services Loss of work time due to lymphedema





Economic cost without lymphedema management (in millions of US$) 47.4 39.2 57.0 47.4 58.8
Economic cost with lymphedema management (in millions of US$) 21.3 19.2 23.5 21.3 27.1
Reduction in economic cost with lymphedema management
(in millions of US$)
26.1 20.0 33.6 26.1 31.7
Reduction in economic cost per person with lymphedema
management (in US$)
1,648 1,263 2,119 1,648 1,998
*Stages 1–2 = 0%; stage 3 = 20%; stage 4 = 50%; stages 5–7 = 100%.
†Stage 1 = 0%; stage 2 = 10%; stage 3 = 25%; stage 4 = 50%; stages 5–7 = 100%.
conservative, we reestimated our model to produce a 15.2%
total loss in work time, just below the mean work time loss
found in other research. Doing so raised the per-person
reduction in economic burden of lymphedema and ADLA by
21%, from US$1,648 to US$1,998, at 4% rate of growth of
real wages and costs and 3% discount rate. The comparison
of results with baseline parameters and sensitivity analysis is
shown in Supplemental Table 3.
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